- Home
- SENEB vs VSTM Comparison
SENEB vs VSTM Comparison
Compare SENEB & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | VSTM |
|---|---|---|
| Founded | 1949 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.0M | 723.8M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | SENEB | VSTM |
|---|---|---|
| Price | $111.87 | $7.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 721.0 | ★ 2.1M |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | $13,379,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | $271.39 |
| P/E Ratio | $12.78 | ★ N/A |
| Revenue Growth | 8.33 | ★ 33.79 |
| 52 Week Low | $71.47 | $3.46 |
| 52 Week High | $124.94 | $11.25 |
Technical Indicators
Market Signals| Indicator | SENEB | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 32.81 |
| Support Level | $108.68 | $9.13 |
| Resistance Level | $113.20 | $9.91 |
| Average True Range (ATR) | 0.45 | 0.60 |
| MACD | -1.46 | -0.31 |
| Stochastic Oscillator | 19.61 | 1.67 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.